Bimzelx (bimekizumab-bkzx) / UCB, BRL Medicine - LARVOL DELTA

Achieving complete skin clearance was associated with cumulative benefits on disease impact up to 2 years in patients with psoriatic arthritis and psoriasis treated with bimekizumab (EADV 2025) - P3 | "In patients with PsA and concomitant moderate-to-severe psoriasis, complete skin clearance with bimekizumab was associated with greater cumulative benefits on patient-reported disease impact over 2 years."

Clinical • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Interim analysis of a European real-world study on the effectiveness and physician satisfaction of bimekizumab treatment in patients with psoriatic arthritis: insights from France, Germany, Spain and the United Kingdom (EADV 2025) - "A high proportion of physicians were satisfied/very satisfied with the disease control provided by BKZ in their pts; nearly all physicians reported being satisfied/very satisfied with treatment for pts who had been prescribed BKZ for ≥3 months. These results complement rapid and sustained responses on BKZ reported in the phase 3 trials and confirm the effectiveness of BKZ in pts with PsA in routine clinical practice."

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Bimekizumab demonstrated sustained efficacy and safety across the full spectrum of axial spondyloarthritis: 3-year results from two phase 3 studies and their open-label extension (EADV 2025) - "BKZ showed sustained clinical response and was well tolerated through 3 yrs across axSpA; most pts achieved ASAS40 and ASDAS LDA. These results support BKZ as a long-term treatment for the full spectrum of axSpA."

Clinical • P3 data • Ankylosing Spondylitis • Candidiasis • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Novel Coronavirus Disease • Ocular Inflammation • Ophthalmology • Psychiatry • Respiratory Diseases • Seronegative Spondyloarthropathies • Spondylarthritis • Suicidal Ideation • Uveitis • IL17A

Spesolimab as treatment option for refractory Acrodermatitis Continua of Hallopeau (EADV 2025) - "Following this, she was treated with various systemic therapies (acitretin, fumaric acid esters, glucocorticoids, methotrexate, cyclosporine), several biologics (ustekinumab, secukinumab, adalimumab, ixekizumab, guselkumab, apremilast, anakinra, infliximab, risankizumab, brodalumab, bimekizumab, tildrakizumab), Janus kinase inhibitors (tofacitinib, upadacitinib), and a combination of both (risankizumab and tofacitinib)...After the second dose, the patient noted signs of effluvium, which were subsequently treated with topical minoxidil... This case highlights the successful application of spesolimab, a targeted IL-36 inhibitor, as a novel treatment option for a patient suffering from severe refractory acrodermatitis continua of Hallopeau (ACH). To the best of our knowledge, this is the first case of treating acrodermatitis continua of Hallopeau (ACH) with subcutaneous spesolimab.The emergence of effluvium as a potential side effect following treatment necessitates careful..."

Cardiovascular • Dermatitis • Dermatology • Diabetes • Immunology • Metabolic Disorders • Musculoskeletal Pain • Osteoarthritis • Psoriasis • Pulmonary Arterial Hypertension • Pustular Psoriasis • Rheumatology • Type 2 Diabetes Mellitus

Head-to-head study of bimekizumab, an IL-17A/IL-17F inhibitor, and risankizumab, an IL-23 inhibitor, in patients with active psoriatic arthritis: Study design and rationale of BE BOLD, a phase 3b, randomised, parallel-group study (EADV 2025) - "BE BOLD is the first head-to-head study to evaluate efficacy and safety of an IL​17A/IL-17F inhibitor vs an IL-23 inhibitor in patients with active PsA, and the first to test for superiority of bimekizumab over risankizumab in joint disease, using the primary endpoint of ACR50 at Week 16."

Clinical • Head-to-Head • P3 data • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL23A

Efficacy and Safety of Two IL-17 Inhibitors (Bimekizumab and Secukinumab) in the Management of Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs) (EADV 2025) - "Across five placebo-controlled RCTs, IL-17 inhibition with bimekizumab or secukinumab resulted in significant and rapid improvements in lesion clearance, pain reduction, and quality of life without an excess of serious adverse events. These findings support the positioning of IL-17 inhibitors as promising treatment options for patients with moderate-to-severe HS who have not responded to TNF-alpha inhibitors. However, given the limited number of available RCTs and the presence of clinical heterogeneity, additional long-term and head-to-head trials are warranted to confirm efficacy, durability, and safety."

Retrospective data • Review • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • IL17A

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Systematic Review and Meta Analysis of RCTs (EADV 2025) - "Bimekizumab demonstrates superior efficacy compared to placebo in achieving clinically meaningful improvements in disease activity and skin pain in patients with moderate-to-severe HS. Its short-term serious adverse event profile appears acceptable. Bimekizumab represents a promising and effective therapeutic option for this patient population."

Retrospective data • Review • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation

Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis (EADV 2025) - "The therapies included were adalimumab (ADA), ustekinumab (UST), secukinumab (SEC), ixekizumab (IXE), bimekizumab (BIM), brodalumab (BRO), guselkumab (GUS), risankizumab (RIS), as well as biosimilars of adalimumab (ADA BS) and ustekinumab (UST BS). Although IL-17 and IL-23 inhibitors demonstrate high efficacy, initiating treatment with ADA and UST biosimilars as first- and second-line therapies is the most cost-effective strategy for moderate-to-severe psoriasis in the Spanish healthcare setting."

Cost effectiveness • HEOR • Dermatology • Immunology • Psoriasis • IL17A • IL23A

Next-Generation Therapies for Hidradenitis Suppurativa: Recent FDA Approvals and a Look at Clinical Trial Landscape (EADV 2025) - "Over the past decade, numerous immunotherapies have been developed for a wide range of dermatologic conditions, including two recently FDA-approved treatments for HS within the last year (bimekizumab and secukinumab)2,3...Sonelokimab, another IL-17A/F inhibitor, is currently in a recruiting phase 3 trial...Other cytokine-targeting agents are lutikizumab (IL-1α/IL-1β inhibitor), spesolimab (anti-IL-36R), and anifrolumab (type I interferon receptor antagonist)...Agents targeting the JAK-STAT pathway include the JAK1 inhibitors povorcitinib, upadacitinib, and ruxolitinib, as well as deucravacitinib, a tyrosine kinase 2 inhibitor; all are currently under investigation for HS...Remibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, also showed promising results, with 72.7% of patients reaching the HiSCR endpoint at week 167. Brensocatib, a dipeptidyl-peptidase 1 inhibitor, is currently being evaluated in a recruiting phase 3 trial... The last decade has brought a wave..."

Clinical • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • IFNAR2 • IL17A • IL1B • TYK2

Exacerbation of Psoriatic Lesions and Vascular Complications in a Patient Treated with Bimekizumab: A Case Report (EADV 2025) - "Between 2020 and 2023, the patient received methotrexate (15–25 mg/week, orally and subcutaneously), resulting in improvement of joint symptoms but no significant effect on nail involvement...Topical corticosteroids and systemic cyclosporine A provided no significant improvement...Sulodexide was initiated on January 21, 2025, followed by the introduction of oral acitretin (35 mg/day; 0.35 mg/kg) resulting in partial improvement, including slight initial improvement of acral skin involvement... Although rare, cases of vasculitis have been described with other IL-17 inhibitors. A similar mechanism may underlie the adverse effects observed with bimekizumab in this patient. Further research is needed to better understand these associations and to develop personalized treatment strategies that account for individual risk of adverse reactions."

Case report • Clinical • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Vasculitis • IL17A

Effective treatment of psoriasis vulgaris and hidradenitis suppurativa with bimekizumab in a patient with HIV after treatment failure with adalimumab and secukinumab (EADV 2025) - "This case demonstrates that IL-17A inhibition through modern biological therapy is an effective and safe treatment option for patients with psoriasis and HIV. Our findings go along with case reports from Jian Gong et. al."

Clinical • Candidiasis • Dermatology • Hidradenitis Suppurativa • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Pruritus • Psoriasis • CD4 • CD8

Bimekizumab demonstrated long-term efficacy and safety in patients with active psoriatic arthritis who had baseline plaque-type psoriasis and nail involvement: Up to 3-year results from two phase 3 studies (EADV 2025) - P3 | "BE OPTIMAL reference arm (adalimumab 40 mg Q2W) patients switched to BKZ (ADA/BKZ) at Week 52. Patients with PsA who had BL psoriasis and nail involvement treated with BKZ experienced sustained, high levels of treatment response across assessed domains to 3 years; improvements were similar regardless of prior TNFi experience. BKZ was well tolerated, with a safety profile consistent with previous reports."

Clinical • P3 data • Candidiasis • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Nephrology • Novel Coronavirus Disease • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Association of Bimekizumab for refractory pemphigus foliaceus. A report of two cases. (EADV 2025) - " Patient 1: A 57-year-old man with PF since 2018, previously treated with multiple cycles of rituximab, IVIG, mycophenolate, and prednisone, remained clinically active with undetectable peripheral B cells...Patient 2: A 43-year-old man with PF since 2010, resistant to azathioprine, mycophenolate, dapsone, and rituximab (January 2024), began bimekizumab in July 2024... These two cases highlight the potential role of IL-17 blockade in PF, particularly in rituximab-refractory patients. The rapid clinical response and decline in anti-Dsg1 antibody titers suggest that bimekizumab may offer a novel therapeutic option in selected cases. Further studies are warranted to explore its efficacy and safety in autoimmune blistering diseases."

Clinical • Dermatology • Pemphigus Vulgaris • Psoriasis • CD4

High efficacy and safety of Bimekizumab combined with surgery for hidradenitis suppurativa: Findings from a multicentric study[ (EADV 2025) - "Bimekizumab demonstrates remarkable efficacy and safety in the treatment of hidradenitis in clinical practice. The use of combined surgical approach is common in this setting and offers greater effectiveness, together with a good safety profile and an adequate postoperative wound healing process."

Clinical • Surgery • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Obesity

Bimekizumab effect on health-related quality of life and symptoms over 2 years: Data from BE HEARD EXT (EADV 2025) - P3 | "Patients treated with bimekizumab achieved improvements in HRQoL at 1 year, as assessed by both DLQI and the HS-specific HiSQOL, which were maintained to 2 years. Patients treated with bimekizumab also reported that improvements in HS skin pain, itch, smell or odour and drainage or oozing symptoms at 1 year were maintained to 2 years."

Clinical • HEOR • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • IL17A

Bimekizumab maintenance of response over 2 years: Data from BE HEARD EXT (EADV 2025) - P3 | "High proportions of patients treated with bimekizumab who achieved IHS4 outcomes at Week 48 maintained response over 2 years. Among patients treated with bimekizumab who achieved no to mild impact of HS on HRQoL at Week 48, as assessed by HiSQOL response, the majority maintained their response over 2 years. These results illustrate the durability of high levels of response achieved with bimekizumab treatment at 1 year that are maintained to 2 years across outcome measures, in patients with moderate to severe HS."

Clinical • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • IL17A

CR-T1-T4, a tri-specific anti-inflammatory and anti-Th17 protein drug candidate for the treatment of hidradenitis suppurativa (EADV 2025) - "Comparative evaluations of monotherapy and combination therapy were performed with competing agents Bimekizumab and Adalimumab in an HS-mimicking environment using human PBMCs...Histopathological analysis and cytokine profiling post-treatment were used to confirm the efficacy of CR-T1-T4 compared to Bimekizumab, Etanercept, and et cetera... CR-T1-T4 is a tri-specific soluble receptor TRAP protein that targets three key cytokines associated with HS. Our data shows that CR-T1-T4 exhibits a very low ADA response and low infection risk compared to current monoclonal antibody therapies in ex vivo models, while also demonstrating superior neutralizing effects in both in vivo and ex vivo studies. As a tri-specific Fc-fusion protein, CR-T1-T4 may offer a highly effective treatment option for HS patients who do not respond to, or relapse after, existing single-target antibody therapies."

Trispecific • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Psoriasis • IL17A • TNFA

Bimekizumab impact on hidradenitis suppurativa lesions over 2 years: Data from BE HEARD EXT (EADV 2025) - P3 | "Over 2 years, at the patient level, bimekizumab treatment reduced the number of lesions in the majority of individuals. These data show the dynamic, within-patient-level reduction in HS lesions, including draining tunnels, abscesses and inflammatory nodules; such data are important due to the severe long-term sequalae of these lesions."

Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • IL17A

Bimekizumab influences the association between HS skin pain severity and health-related quality of life over 2 years: Data from BE HEARD EXT (EADV 2025) - P3 | "Over 2 years of treatment with bimekizumab, a greater reduction in HS skin pain severity translated into an improvement in health-related quality of life."

Clinical • HEOR • Dermatology • Hidradenitis Suppurativa • Immunology • Pain

Bimekizumab shows high long-term efficacy in the treatment of patients with moderate-to-severe hidradenitis suppurativa in real-world clinical conditions: effect on draining tunnels and the importance of combined therapy (EADV 2025) - "Our study data show that treatment with bimekizumab is effective and safe for patients with moderate-to-severe hidradenitis suppurativa, with a notable impact on the control of draining tunnels. The use of combined medical or surgical treatment, as is common in routine clinical practice for these patients, has a synergistic effect with the drug, resulting in high response rates."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Crohn's disease • Dermatology • Gastroenterology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammatory Bowel Disease • IL17A

Bimekizumab safety and tolerability in patients with moderate to severe hidradenitis suppurativa: 2-year results from BE HEARD EXT (EADV 2025) - P3 | "BKZ was well tolerated in patients with moderate to severe HS over 2 years, with no new safety signals observed in Year 2.4"

Clinical • Candidiasis • Cardiovascular • Congestive Heart Failure • Dermatology • Heart Failure • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • IL17A

New Therapeutic Strategies in Hidradenitis Suppurativa: An Integrative Approach to a Chronic and Debilitating Disease (EADV 2025) - "Conventional treatments include antibiotics (notably tetracyclines and clindamycin-rifampin combinations), systemic retinoids, corticosteroids (systemic or intralesional), and hormonal therapies (anti-androgens and oral contraceptives), particularly for women with mild disease...Adalimumab, an anti-TNF-α agent, is currently the only biologic approved for HS and has demonstrated significant efficacy in phase III trials although with variable long-term outcomes. Other biologics under investigation include infliximab, etanercept, ustekinumab (anti-IL-12/23), and secukinumab (anti-IL-17A), the latter showing rapid clinical improvement when administered biweekly. Moreover, agents such as bimekizumab (dual IL-17A/F inhibitor) and bermekimab (anti-IL-1α) are being evaluated in advanced trials and offer encouraging results...The integration of targeted biologic agents into the therapeutic algorithm represents a significant advancement, particularly for refractory forms of the..."

CNS Disorders • Depression • Dermatology • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Inflammation • Obesity • Pruritus • Psychiatry • IL12A • IL17A • IL1B • IL23A

Treatment of hidradenitis suppurativa with Risankizumab in patients with Crohn's disease (EADV 2025) - "To date, Adalimumab, Secukinumab and Bimekizumab are the only biologic treatments approved for HS. Risankizumab used in IBD dosing represents a safe and effective alternative for patients with moderate to severe HS and CD."

Clinical • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hidradenitis Suppurativa • Immunology • Inflammatory Bowel Disease • Psoriasis • Rheumatology • IL17A • IL23A

Unusual Places, Usual Disease: Ectopic Presentations of Hidradenitis Suppurativa (EADV 2025) - "Bimekizumab treatment was initiated., A 25-year-old woman reported recurrent painful nodules in the left leg, right upper leg, and axilla...The patient had previously received doxycycline and isotretinoin. Due to worsening lesions, adalimumab treatment was planned... We report three female patients with inflammatory nodules and double comedones located in uncommon HS sites. The first case involved facial, scapular, and femoral areas; the second femoral and tibial; and the third dorsal, scapular, and shoulder regions. Identifying these atypically located lesions is crucial for accurate diagnosis and effective treatment of HS."

Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • Psoriasis

Adalimumab as a Therapeutic Approach in PASH Syndrome: A Case Report (EADV 2025) - "The options for biologics in the treatment of HS include adalimumab, a TNF-alpha inhibitor, and secukinumab and bimekizumab, both of which are IL-17 inhibitors. "Was biological therapy required for HS?" is indeed a relevant question. Furthermore, the lesions are integral components of a broader syndrome and must be evaluated together as a whole. This holistic perspective is essential for understanding their full impact on the patient's health and allows for a more tailored, individualized treatment approach, as illustrated in the case presented.** The future is promising, and we are eagerly awaiting what is on the pipeline."

Case report • Clinical • Acne Vulgaris • Cardiovascular • Dermatology • Hidradenitis Suppurativa • Immunology • Metabolic Disorders • Musculoskeletal Diseases • Pyoderma Gangrenosum • Rheumatology • IL17A • IL1B